Since the emergence of the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks.
BlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.
The U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the Covid-19 pandemic.
According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.
Scientists at the National Institutes of Health (NIH) launched a trial to examine a potential universal flu vaccine candidate, known as H1ssF_3928.
New research indicates that llamas may hold the key to flu vaccines.
Japan’s Shionogi and Swiss drugmaker Roche won U.S. FDA approval for Xofluza, the first new flu drug approved by the regulatory agency in nearly 20 years.
Outcome Health launched a flu education campaign across its platform to help patients understand the risk of contracting the flu and how to take precautionary measures.
Dr. Brenda Fitzgerald resigned her post as director of the U.S. Centers for Disease Control and Prevention over financial conflicts of interest, the U.S. Department of Health and Human Services (HHS) said.
Seniors who get a flu shot every year are less likely to be hospitalized with severe influenza infections or to die from them than those who get vaccinated only sporadically, a study suggests.